Late-breaking one-year data show Abbott's next-generation Amulet 360™ device continues to demonstrate high rates of left atrial appendage closure and low incidence of stroke
Key Highlights
- ➤Amulet 360 achieved 96.3% complete LAA closure at one year
- ➤More than 98% remained free from ischemic stroke or systemic embolism
- ➤More than 99% avoided intervention-requiring pericardial effusion
- ➤Amulet 360 remains investigational in the U.S.; received CE Mark approval in August 2026
Expert Statements
DJ Lakkireddy, M.D., Executive medical director of the Kansas City Heart Rhythm Institute, professor of medicine at the University of Missouri and president-elect of the Heart Rhythm Society
“For patients with non-valvular atrial fibrillation who require an alternative to long-term oral anticoagulation, achieving durable and complete left atrial appendage closure is an important clinical goal”
DJ Lakkireddy, M.D., Executive medical director of the Kansas City Heart Rhythm Institute, professor of medicine at the University of Missouri and president-elect of the Heart Rhythm Society
“The VERITAS trial results are highly encouraging, demonstrating high rates of complete closure sustained through 12 months.”
DJ Lakkireddy, M.D., Executive medical director of the Kansas City Heart Rhythm Institute, professor of medicine at the University of Missouri and president-elect of the Heart Rhythm Society
“These findings reinforce the potential of the Amulet 360 technology to provide physicians with an effective treatment option as we continue to advance strategies for stroke risk reduction in this patient population.”
Christopher Piorkowski, M.D., Chief medical officer of Abbott's electrophysiology business
“Physicians treating patients with non-valvular atrial fibrillation need solutions that can perform consistently across the broad range of left atrial appendage anatomies they encounter in practice.”
Christopher Piorkowski, M.D., Chief medical officer of Abbott's electrophysiology business
“Amulet 360 was designed with enhanced conformability and sealing features intended to support durable closure across a wider range of anatomies.”
Christopher Piorkowski, M.D., Chief medical officer of Abbott's electrophysiology business
“The one-year VERITAS results reinforce the potential of these next-generation enhancements to expand patient choice and help physicians confidently offer left atrial appendage closure to patients at the right time in their care journey.”
Late-breaking one-year data show Abbott's next-generation Amulet 360™ device continues to demonstrate high rates of left atrial appendage closure and low incidence of stroke PR Newswire
* Late-breaking one-year VERITAS study results were presented at the Transcatheter Cardiovascular Therapeutics conference and simultaneously published in JACC: Cardiovascular Interventions; data show the device achieved high closure rates of the left atrial appendage (LAA) and a low incidence of stroke * Abbott's Amulet 360™ LAA Occluder is a next-generation device designed to reduce the risk of stroke and other serious blood clot-related complications in people with atrial fibrillation not caused by a heart valve issue ABBOTT PARK, Ill., Nov. 2, 2026 /PRNewswire/ -- Abbott (NYSE: ABT), the global healthcare leader, announced today one-year results for its investigational Amulet 360™ Left Atrial Appendage (LAA) Occluder from the VERITAS study, which show meaningful closure rates of the left atrial appendage and a low incidence of stroke in people with atrial fibrillation (AFib) not caused by a heart valve issue. The data were presented in a late-breaking session at the Transcatheter Cardiovascular Therapeutics (TCT) conference in San Diego, Calif., on Nov. 1, 2026, and simultaneously published in JACC: Cardiovascular Interventions .
Get started
Create a free account to read the full story.